Everolimus for Patients With Relapsed/Refractory Germ Cell Cancer
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether the drug everolimus is effective in the
treatment of patients with relapsed cancer of the testis. This is a phase II study where all
patients will receive the study drug (everolimus 10 mg daily). The primary endpoint of the
study is the rate of patients that have no progressive disease after 12 weeks of treatment.
Twenty-five evaluable patients will be treated in this study.